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factor of activated T cells 1 drives
IL-9–mediated allergic asthmaTo the Editor:
Nuclear factor of activated T cells (NFAT) is a family of
transcription factors activated by dephosphorylation mediated by
Ca11-activated calcineurin. NFAT coordinates different aspects
of T-cell development and activation of T, B, natural killer, and
mast cells and is the target of the immunosuppressive drug
cyclosporin A.1 We reported recently that targeted deletion
of NFATc1 in T cells resulted in inhibition of TH2 and TH17
differentiation.2
Here we first investigated NFATc1 mRNA expression in
PBMCs isolated from healthy and asthmatic children from the
PreDicta cohort. Children with allergic asthma expressed
significantly more NFATc1 mRNA than healthy control subjects
(Fig 1, A-C, and Tables I and II). Furthermore, we found that
asthmatic children with a positive skin test result had significantly
increased expression of NFATc1 mRNA compared with
healthy control subjects (Fig 1, D, and Tables I and II). These
results suggested that NFATc1 might have a role in allergic
asthma. Consistent with a TH2-inducing function of NFATc1
and a TH2 cytokine inhibitory property of the TH1 cytokine
IFN-g (IFNG), levels of this TH1 cytokine were found to be
downregulated in children with asthma and a positive skin test
result (Fig 1, E).
As in PBMCs from the PreDicta cohort, NFATc1 showed
altered expression levels in peripheral blood CD41 T cells from
300 children and adults from the Asthma BRIDGE cohort
(P < .05; Fig 1, F, and Table III). This cohort was described
previously by Raby et al,3 and some of the microarray data
regarding genes other than NFATc1 and IRF4 were described
before.4 Both the PreDicta study and the Asthma BRIDGE study
used the same phenotype definitions. The shorter isoform
A (variant 1) lacks the C-terminal extension of approximately
245 amino acids that is present in all other NFAT proteins. This
isoform of NFATc1 was found to be significantly overexpressed
in peripheral blood CD41 T cells from asthmatic patients with
a positive skin test result compared with both asthmatic patients
with a negative skin test result and nonasthmatic subjects with a
negative skin test result (Table III). Moreover, the induced
isoform D (variant 4) of NFATc1 was also found to be
differentially expressed between asthmatic patients with a
positive skin test result and nonasthmatic subjects with a negative
skin test result (Table III). The log fold change (FC) for NFATc1
expression was 0.21 (1.2-fold increase), with an average
expression of 7.44 (P5 .013). The log FC for NFATc1 expression 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).was 0.1 (1.1-fold increase), with an average expression of 7.83
(P5 .013). Adding the 84 white asthmatic patients with positive
skin test results to the model and adjusting for age, race, and sex
(146 black plus 84 white vs 39 black subjects; female/male ratio,
127:106) did not change the NFATc1 result (log FC 5 0.1,
P 5 .018). Induction of the short isoform A of NFATc1 takes
place after activation of T cells and is controlled by promoter 1
(Fig 1, A), a strong inducible promoter. This effect is autoregu-
lated by the NFAT transcription factors.5 NFATc1/A is thought
to be needed for exerting effector functions in activated T cells.
In contrast to NFATc1/C, NFATc2, and NFATc3 proteins, the
short isoform A of NFATc1 is not able to promote cell apoptosis.5
We presume that this function of NFATc1 leads to a prolonged
survival of effector T cells in asthmatic patients with a positive
skin test result. Moreover, it has been observed that NFATc1/
aA (Fig 1, A) is the most prominent NFATc1 protein on receptor
stimulation of peripheral B and T cells. In these cells the first
activation, through the respective receptor, of the full induction
of NFATc1/aA requires 24 hours. By contrast, this isoform is
completely induced within a few hours after secondary
stimulation.5 This is in line with our findings that NFATc1/A is
upregulated in CD41 T cells of asthmatic patients with a positive
skin test result because these patients were already sensitized to
an allergen. Moreover, we observed that NFATc1 isoform D
(variant 4) was upregulated in asthmatic patients with a positive
skin test result. To our knowledge, the function of NFATc1/D
has not been described yet.
In addition to NFATc1, the transcription factor interferon
regulatory factor 4 (IRF4), which is encoded by the IRF4 gene,
has been shown to play a role in the differentiation of various
T-cell subsets known to have an effect on asthma pathology.6
Therefore we investigated IRF4 mRNA expression in whole
blood from healthy and asthmatic children from PreDicta
(Fig 2, A). We found that the asthmatic children had a signifi-
cantly increased expression of IRF4 compared with that seen
in healthy control subjects (Fig 2, A), especially when they
also had a positive skin test result (Fig 2, B). This observation
was further confirmed by analyzing total blood cells in Asthma
BRIDGE asthmatic patients with positive skin test results
(P 5 .02; Fig 2, C). IRF4 is known to be an important factor
for innate and adaptive immune responses, cooperating with
various other transcription factors, including NFAT family mem-
bers, to act as both a transcriptional repressor and activator.7
Therefore it is likely that IRF4 interacts with NFATc1 to prolong
the survival of effector T cells in patients with allergic asthma.
Namely, IRF4 would directly promote the production of IL-4,
one of the TH2-associated cytokines that contributes to asthma
pathogenesis, by binding to the IL-4 promoter in cooperation
with NFATc1. In support of this notion, we found reduced
IFNG mRNA expression in the group of children with positive
skin test results who had higher levels of NFATc1 and IRF4.
Consistently, we previously reported that asthmatic mice defi-
cient in NFATc1 in T cells (NFATc1fl/flxCD4Cre) have increased
numbers of IFN-g1CD41 T cells in their lungs and that these
cells expressed less Batf, a transcription factor essential for
immunoglobulin class-switching that cooperates with IRF4 at
the promoter of different genes relevant for asthma8 and that
NFATc1fl/flxCD4Cre mice have reduced serum levels of
ovalbumin (OVA)–specific IgE.2 Moreover, these data are also
supported by our findings in the basic leucine zipper transcription
factor, ATF-like (BATF)–deficient mice, which do not induce
FIG 1. Increased expression of NFATc1 in atopic children with asthma. A, NFATc1 gene transcript isoforms
or variants. B, Schematic representation of the PreDicta analysis. C, NFATc1 mRNA expression was
analyzed by using quantitative real-time PCR in PBMCs (n 5 12-17 children per group). D, Children shown
in Fig 1, C, were further subdivided into healthy children with negative skin test results (n5 5) and asthmatic
children with positive skin test results (n 5 13). E, IFNG mRNA expression analyzed by using quantitative
real-time PCR in RNA isolated fromwhole blood (n5 6 and 15 children per group). F, Schema of the subjects
and their obtained gene expression profiles from Asthma BRIDGE Cohort. Statistical significance in this
figure was evaluated with the Student t test. *P <_ .05 and **P <_ .01. Data are presented as means 6 SEMs.
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levels9 in a model of allergic asthma.
Because IRF4 is also known to be crucial for IL-9 production,6
we also investigated IL-9 in cultured PBMCs of preschool chil-
dren stimulated with PHA. We could not find any differences in
IL-9 productionwhenwe compared asthmatic and healthy control
children (Fig 2, D), but we observed a significant increase in IL-9
levels in the supernatants of PBMCs isolated from asthmatic
children with an additional positive skin test result compared
with those isolated from healthy children with a negative skin
test result (Fig 2, E).
Both NFATc1 and IRF4 also positively influence IL-9
production of TH9 cells.
6 Consistent with the increased
expression of both IRF4 and NFATc1 seen in asthmatic patients
with positive skin test results, we also found increased IL-9 levels
in their PBMCs.
Overall, we found that in PBMCs and CD41 T cells of
asthmatic patients with a positive skin test result, expression ofNFATc1 isoforms and IRF4 was increased, suggesting a funda-
mental role for both transcription factors in the immunologic
switch in allergic asthma. In this survey we analyzed subjects
from 2 different studies. Although the PreDicta study includes
only 42 children, we obtained important indications regarding
NFATc1, IRF4, and IL-9 expression in patients with allergic
asthma. These results could be verified and confirmed in the
bigger cohorts of the Asthma BRIDGE study, in which 300
asthmatic patients and 122 control subjects were included. The
functional relevance of NFATc1 in asthmatic patients was
supported by our observations in targeted conditional deletion
of NFATc1 in T lymphocytes, where Nfatc1/AmRNA expression
perfectly correlated with OVA-specific IgE levels (R2 5 0.94) in
patients with experimental asthma (see Fig E1, D, and
the Methods, Results, and Discussion sections in this article’s
Online Repository at www.jacionline.org) and resulted in
downregulation of IL-9 (see Fig E1, B) and mast cell
function (see Figs E2 and E3 and the Methods, Results, and
TABLE I. Clinical outcome of children with asthma participating in the WP1-UKER cohort in the European PreDicta study
Group/patient Age (y) Sex
PBMCs














1 6 M 1.75 Positive 126 C MOPA 0 0
2 6 M 2.27 Positive 80 PC MOPA 0 3
3 5 F 2.05 Positive 108 PC MIPA 25 —
4 6 M 1.98 Positive 128 C MIPA 0 1
5 5 M 2.58 Positive 102 PC I 0 4
6 5 F 2.62 Positive 129 C I 0 1
7 5 M 2.32 Positive 143 PC I 0 4
8 6 F 1.57 Positive 94 PC I 0 3
9 4 M 1.96 Positive 115 PC MOPA 0 3
10 5 F 1.93 Positive 92 U MOPA 0 15
11 6 F 2.05 Positive 111 C I 0 2
12 5 M 1.14 Positive 99 C I 0 0
13 4 F 2.89 Negative 135 C I 0 4
14 4 M 1.91 ND 96 C I 5 4
15 5 M 1.29 Positive 80 C I 0 2
16 5 M 1.83 Positive 86 C I 0 1
17 5 M 2.50 Positive 107 C I 0 2
18 4 M 1.54 Positive 71 PC I 0 3
19 4 M 2.20 Negative 86 C I 0 3
20 5 F 2.27 ND 98 C I 0 1
21 5 F 1.77 Negative — U MIPA 0 20
22 5 M 1.39 Positive 81 C MIPA 0 3-5
Mean 5.00 14 M 1.99 103.19 1.36
SEM 0.14 8 F 0.09 4.20 1.15
B0, Baseline visit; C, controlled; F, female; I, intermittent; M, male; MIPA, mild persistent asthma; MOPA, moderate persistent asthma; ND, not done; PC, partially controlled;
U, uncontrolled; UKER, Uniklinikum Erlangen; WP1, Work Program 1.
TABLE II. Clinical outcome of control children participating in the WP1-UKER cohort in the European PreDicta study
Group/patient Age (y) Sex
PBMCs








1 6 M 1.14 ND — 0 —
2 6 F 2.95 ND 121 0 —
3 5 F 1.79 Negative 81 0 —
4 4 M 2.01 ND — 0 —
5 6 M 1.41 ND 105 0 —
6 4 F 2.14 ND 109 0 —
7 6 M 2.86 ND 87 0 —
8 4 M 1.73 Negative 100 0 —
9 5 F 1.67 ND 112 0 —
10 5 F 2.01 Positive 119 0 —
11 4 M 2.43 Positive 116 0 —
12 5 M 2.32 ND 111 0 —
13 4 M 2.40 Negative 109 0 —
14 4 F 1.60 Negative 109 0 —
15 5 M 2.22 Negative 92 0 —
16 4 M 2.88 Negative — 0 —
17 4 M 1.38 Negative 109 0 —
18 5 M 1.13 ND 110 0 —
19 4 M 1.77 ND 118 0 —
20 5 F 1.50 ND — 0 —
Mean 4.75 13 M 1.97 106.75 0
SEM 0.17 7 F 0.12 2.48 0
B0, Baseline visit; F, female; M, male; ND, not done; UKER, Uniklinikum Erlangen; WP1, Work Program 1.
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TABLE III. Comparison between different groups of children and
adults with or without asthma and atopy (Asthma BRIDGE)
Group comparisons Asthma 1, skin test 1 (n 5 251)
Asthma 2, skin test 1 (n 5 44) P 5 .1
Asthma 1, skin test 2 (n 5 47) P 5 .006 (NFATc1 isoform A)
Asthma 2, skin test 2 (n 5 75) P 5 .002 (NFATc1 isoform A);
P 5 .05 (NFATc1 isoform D)
For analysis using a microarray, there were 47,009 tag probes to target individual
exons, including 4 exon sequences linked to specific NFATc1 isoforms. The particular
isoforms of NFATc1 mRNA were as follows: NFATc1 isoform A 5 variant 1; NM
172390.2; NP 765978.1; NFATc1 isoform D5 variant 4; NM 172388.2; NP 765976.1;
Gene ID: 4772. P values for association of probes with phenotypes were adjusted by
using the Benjamini-Hochberg method for multiple comparisons between groups.
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LETTERS TO THE EDITOR 1901Discussion sections in this article’s Online Repository at
www.jacionline.org). Therefore targeting NFATc1 in T
lymphocytes might ameliorate the allergic phenotype seen in
asthmatic patients.
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bacteria after recreational swim-
ming in a lakeTo the Editor:
Here, we report a case of an 11-year-old white girl who had
an allergic reaction manifesting as severe facial swelling with
periorbital edema and an erythematous pruritic blistering rash
over her arms and hands (Fig 1) after playing and swimming in
Lake Ontario at Presque Isle State Park. After repeated handling
of algae making ‘‘bird’s nests,’’ the patient put sunscreen on her
arms and face and then went swimming in the lake for 20 mi-
nutes. The exact time of the onset of the reaction is unknown
because it began a few hours after she went to sleep. The
next morning, she awoke with erythematous itchy swollen
arms, face, and eyes and over time had facial and periorbital
edema. Soon thereafter, she lost consciousness for approxi-
mately 30 seconds.
She was taken to an emergency department in Ontario, where
shewas given diphenhydramine and a dose of cetirizine. Her body
temperature was normal, and over 1 to 2 hours, her rash and
swelling began to subside. However, she still required diphenhy-
dramine every 4 to 6 hours because her rash appeared toworsen as
the previous dose wore off. The photograph of this initial reaction
was taken 2 days after onset (Fig 1, A), demonstrating a red facial
rash with edema.
On the third day after the initial exposure, she awoke with a
worsening rash and againwas taken to the emergency department,
where she was prescribed oral corticosteroids for 5 days and
advised to continue the use of diphenhydramine every 4 to 6 hoursor cetirizine. One day after discontinuing the corticosteroids,
approximately 8 days after the initial reaction, she experienced
itching, and blisters appeared on her hands (Fig 1, B). She was
seen by an allergist who prescribed an epinephrine autoinjector
and topical corticosteroids for the hands; the rash and blisters
completely resolved after 10 days.
Her mother subsequently confirmed with Canadian environ-
mental health officials that the lake had an overgrowth of
freshwater Cyanobacteria. Skin prick test responses to common
aeroallergens were negative. Patch testing was also performed to
exclude a reaction to the sunblock, and a thorough history was
obtained to exclude other underlying causes. Interestingly,
despite being nonatopic, a serum sample sent to our laboratory
showed increased specific IgE levels to Cyanobacteria extract.
This study’s objective was to determine whether the patient’s
specific IgE to Cyanobacteria was functionally relevant and to
compare the allergenicity of various Cyanobacteria species.
Cyanobacteria (also known as blue green algae) are a phylum
of bacteria that grow in brackish and fresh water environments
and are capable of producing toxins. Apart from their toxicity,
Cyanobacteria are sensitizing in susceptible subjects.1 Sensitiza-
tion has been attributed to several Cyanobacteria genera and spe-
cies, includingArthrospira species,Oscillatoria species, Lyngbya
species, Anabaena species Synechocystis species, Aphanizome-
non flos-aquae, andMicrocystis species.1-5 More recently, severe
cases of anaphylaxis have been reported after ingestion of spiru-
lina tablets containing the Cyanobacteria genus Arthrospira.2,3 In
all of these cases, the causes of sensitization have been diverse in
terms of the Cyanobacteria species implicated, raising the possi-
bility of cross-reactivity of various Cyanobacteria species. In
Lake Ontario, for example, a number of Cyanobacteria genera
and species have been detected, including Synechococcus spe-
cies, Oscillatoria species, Anabaena species, Aphanizomenon
species, and Microcystis aeruginosa, with the latter being the
most dominant species.6 Previously, phycocyanin of M aerugi-
nosa was shown to be responsible for causing sensitization in a
subset of patients with chronic rhinitis, and the toxicity of these
organisms is inversely proportional to their allergenicity.1,7
Because all Cyanobacteria species produce phycocyanin, we
investigated whether the patient was sensitized to 1 or more
species of Cyanobacteria. After obtaining an informed consent
approved by the University of Cincinnati which allows analysis
of serum for a spectrum of allergic conditions, we performed an
IgE-specific ELISA with serum from the patient and extracts
from a variety of laboratory strains of Cyanobacteria. The results
indicate varying degrees of cross-reactivity with the majority of
Cyanobacteria species (Fig 2, A). Although extracts from the
microcystin-nonproducing strain of M aeruginosa (MC[2]; no.
2) and Synechococcus species (no. 5) showed the most reactivity,
the extracts from Nostoc species (no. 3) and Scytonema species
(no. 8) did not possess any IgE reactivity. Interestingly,
IgE-specific reactivity was also observed to Arthrospira species
(no. 10), which, as previously mentioned, has been associated
with anaphylaxis.2,3
M aeruginosa phycocyanin shows greater than 70% sequence
similarities with phycocyanin from various species of Cyanobac-
teria (see Table E1 in this article’s Online Repository at www.
jacionline.org). To test whether the allergen in these species is
the same as the allergen found in MC(2), we performed an
ELISA inhibition assay using plates coated with Synechococcus
species lysate (solid phase), with MC(2) lysate as the serum
METHODS
Participants (PreDicta study)
Two cohorts of preschool-aged children with and without asthma at the age
of 4 to 6 years were recruited at the Children’s Hospital of Erlangen,
Department of Pediatrics and Adolescent Medicine. This research
was conducted through the European study ‘‘Post-infectious immune
reprogramming and its association with persistence and chronicity of
respiratory allergic diseases’’ (PreDicta), a multicenter prospective cohort
study carried out in 5 different centers in Europe. The study was approved by
the ethics committee of the Friedrich-Alexander University Erlangen-
N€urnberg, Germany (reference no. 4435), and is also registered in the German
Clinical Trial Register (registration no. DRKS00004914). Informed
consent was obtained from the parents of all children of the PreDicta study.
Twenty-two asthmatic patients and 20 healthy subjects were analyzed.
Inclusion criteria for cases were age of 4 to 6 years, gestational age of
36 weeks or greater, and diagnosis of asthma within the last 2 years confirmed
by a doctor of the Children’s Hospital in Erlangen of mild-to-moderate
persistent severity according to Global Initiative for Asthma (GINA)
guidelines (2005). In this study we have assessed the degree of asthma as
follows.
Severity level I is defined as intermittent asthma. The children are free of
asthma symptoms for at least 2 months with an FEV1 of greater than 80%
and a mean expiratory flow (MEF) of greater than 60%.
Severity level II is defined as mild persistent asthma. The children are
symptom free for a period of less than 2 months. At the moment, they do
not have asthmatic symptoms, with an FEV1 of greater than 80% and an
MEF of greater than 60%.
Severity level III is defined as moderate persistent asthma. The children
have asthma symptoms several days a week with an FEV1 of less than 80%
and an MEF of less than 65%. At the B0 visit, parents were asked to answer
questions about asthma control according to 2009 GINA guidelines. Possible
answers were as follows: (1) severity I, which means controlled asthma;
(2) severity II, which means partly controlled asthma; and (3) severity III,
which means uncontrolled asthma.
The GINA guidelines take into account FEV1, limitation of physical
activity, frequency of exacerbations, and use of asthma ‘‘reliever’’ medication.
Exclusion criteria were severe or brittle asthma, children receiving
immunotherapy or more than 6 courses of oral steroids during the preceding
12 months, and children with other chronic respiratory diseases (cystic
fibrosis, bronchopulmonary dysplasia, and immunodeficiencies), except
allergic rhinitis. Furthermore, children with other chronic diseases or chronic
medication use, except atopic eczema, were excluded. The children performed
a peak expiratory flow maneuver. Atopy was proved by at least 1 positive skin
prick test response (wheal size, >_3 mm; HAL Allergie GmbH, D€usseldorf,
Germany). For skin prick tests, we analyzed allergic reactions to the following
allergens: cat, house dust mite, Alternaria species, birch, grass, Ambrosia
species, andmold. Asthmawas confirmed by a physician’s diagnosis of mucus
production, airway hyperresponsiveness, and dyspnea. At visit B0, the doctor
asked the mother several questions to evaluate the child’s asthma symptoms
during the last 12 months. The control subjects had no history of asthma,
wheezing, or atopic illness.
Isolation and culture of human PBMCs (PreDicta
study)
Peripheral blood from control or asthmatic children was collected into
venous blood collection tubes with lithium heparin (BDVacutainer Tubes; BD
Biosciences, San Jose, Calif); the heparinized bloodwas transferred to a sterile
15-mL tube and diluted with an equal volume of warm saline and mixed well.
The diluted blood was carefully stratified on top of the density gradient
medium Biocoll separating solution (Biochrom AG, Berlin, Germany) and
centrifuged. Afterward, the layer of PBMCs, which can be found between
plasma and Biocoll, was transferred to a new sterile 15-mL tube. After
washing the cells twice with RPMI 1640 medium, cells were used for RNA
isolation, as described below. Some of the cells were cultured in complete
culture medium for 48 hours with PHA (10 mg/mL). The complete culture
medium consisted of RPMI-1640 supplemented with 25 mmol/L HEPES and
L-Glutamine (Gibco, Invitrogen, Thermo Fisher Scientific, Waltham, Mass),
100 IU/mL penicillin (Sigma-Aldrich, St Louis, Mo), 100 mg/mL
streptomycin (Sigma-Aldrich), 50 mmol/L b-mercaptoethanol (Sigma-
Aldrich), 200 mmol/L 1% L-glutamine (Sigma-Aldrich), 1% MEM Vitamin
(Sigma-Aldrich), 1% nonessential amino acids (Sigma-Aldrich), 1% sodium
pyruvate (Sigma-Aldrich), and 10% H-FBS (Sigma-Aldrich).
RNA isolation from whole blood (PreDicta study)
Additionally, whole blood from each child from the PreDicta cohort was
collected into Tempus Blood RNATubes (Life Technologies, Carlsbad, Calif)
and stored at 2808C. RNA was isolated and purified by using RNA binding
beads with a MagMAX for Stabilized Blood Tube RNA Isolation Kit
(Ambion, Life Technologies), according to the manufacturer’s instructions.
Isolation of human CD41 T cells (Asthma BRIGDE
study)
Asthma BRIDGE is an open-access biorepository for subjects participating
in genetic studies of asthma in the EVE Consortium.E1 Sample collection and
processing were carried out at each institution according to standardized and
validated protocols. These samples were centralized at the Data Coordinating
Center at the Channing Division of Network Medicine at Brigham and
Women’s Hospital at the Harvard Medical School (Boston, Mass).
Contributing centers isolating peripheral blood CD41 T lymphocytes used a
modified version of the protocol previously optimized for collections in the
Childhood Asthma Management Program study by using anti-CD41
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and column
separation. The modification includes isolating PBMCs and then stimulating
them with PHA before CD41 lymphocyte isolation.
NFATc1 and IRF4 microarray analysis of human
peripheral blood CD41 T cells or whole blood cells
(Asthma BRIDGE study)
NFATc1 alone or in cooperation with IRF4 is known to be important for the
differentiation of different subsets of lymphocytes that play a crucial role in
asthma development.E2-E6 To analyze these factors, microarray analysis was
used within the Asthma BRIDGE study. Therefore samples for RNA extrac-
tion were collected with BDVacutainer CPT tubes (BD Diagnostics, Franklin
Lakes, NJ), placed on ice, and centrifuged within 1 hour (20 minutes at 1700
relative centrifugal force). Total RNAwas extracted by using the RNeasyMini
Protocol (Qiagen, Valencia, Calif) and stored at 2808C. Analysis with the
2100 Bioanalyzer (Agilent Technologies, Santa Clara, Calif) confirmed
average total RNA yields of 2 mg per collection, with minimal evidence of
RNA degradation and 28S/18S ratios approaching 2.0. Some of themicroarray
data regarding genes other than NFATc1 and IRF4were described before.E7,E8
For our differential expression analyses, we studied 300 asthmatic Asthma
BRIDGE subjects with log2-transformed and quantile-normalized gene
expression (n 5 47,009 probes) from unstimulated blood-derived CD41
T cells measured with Illumina Human HT-12 v4 BeadChips (Illumina, San
Diego, Calif). Asthma was defined based on having a doctor’s diagnosis of
the disease with evidence of reversible airflow obstruction with a bronchodi-
lator. The R Bioconductor limma package (version 3.20.1)E9 was used to
perform differential expression analysis. A linear model was fitted along
with implementation of empiric Bayes statistics to assess whether expression
levels of the candidate gene NFATc1 were significantly altered among
asthmatic patients after stratifying by race and adjusting for age and sex.
Two differential expression analyses were performed: (1) comparing asth-
matic patients with positive skin test results (defined as a wheal >_3 mm in
size) with atopic dermatitis (eczema) with those without eczema and
(2) comparing asthmatic patients with positive skin test results with those
with negative skin test results.
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Adult asthmatic patients with positive skin test
results (Asthma BIRDGE study)
Eighty-seven white asthmatic patients with positive skin test results were
identified within the Asthma BRIDGE study. After removing those asthmatic
patients with missing information on unknown conditions of atopic eczema or
skin tests, 82 subjects (female/male subjects, 34/48), consisting of 49
asthmatic patients with eczema and positive skin test results and 33 asthmatic
patients without eczema and positive skin test results, remained for analysis.
One hundred forty-seven black asthmatic patients with positive and
negative skin test results were identified within the Asthma BRIDGE study.
After removing 1 subject withmissing information, 146 subjects (female/male
subjects, 91/55), consisting of 107 asthmatic patients with positive skin test
results and 39 asthmatic patients with negative skin test results, remained for
analysis.
Mice
NFATc1fl/fl control mice and NFATc1fl/flxCD4Cremicewere on a C57BL/6
background and kept in house under specific pathogen-free conditions. Mice
were 6 to 8 weeks old in all experiments. The experiments were performed
with approved licenses (23-177-07/G09-1-008 from the ethical review board
Rheinland-Pfalz and 54-2532.1-2/10 and 54-2532.1-55/12 from the
government of Mittelfranken, Bavaria).
Allergen sensitization and challenge
For the experimental asthma model, mice were sensitized with OVA
(100 mg; Calbiochem, San Diego, Calif) complexed with alum (10%;
Sigma-Aldrich, Steinheim, Germany) on days 0 and 7 administered
intraperitoneally. Allergen challenge was performed with an intranasal
treatment of OVA (2 mg/mL) on days 18, 19, and 20, as described
previously.E10 Mice were killed on day 21, and lung cells were isolated.
Isolation of murine lung CD41 T cells
CD41 T cells were purified from isolated total lung cell suspensions, as
previously described.E11 Shortly, total lung cells were incubated with
anti-mouse CD4 L3T4 microbeads and positively sorted in a magnetic cell
sorter system (MACS; Miltenyi Biotech, Germany), according to the manu-
facturer’s protocol. Afterward, CD41 T cells were cultured in RPMI with
plate-bound a-CD3 (2 mg/mL) and soluble a-CD28 (2 mg/mL) antibodies
for 24 hours in a density of 106 cells/mL. Supernatants were analyzed by
means of ELISA for protein production.
Isolation and differentiation of murine bone
marrow–derived mast cells
Hind legs of the mice were prepared, and bone marrow cells were flushed
from the tibias and femurs with sterile PBS. Afterward, cells were centrifuged
for 5minutes at 48C and 1500 rpm. Cells were then resuspended in RPMI 1640
culture medium supplemented with 10% FBS, 1% penicillin/streptomycin,
1% L-glutamine, 1% HEPES, 50 mmol of b-mercaptoethanol, and 10 ng/mL
IL-3 and stem cell factor (PeproTech, Hamburg, Germany) and cultured for
4 weeks in 10 mL of the medium in small culture flasks, as previously
described.E12 Some of the cells were additionally cultured with 10 ng/mL
recombinant IL-9 (PeproTech). Every week, medium with cytokines was
replaced, and fluorescence-activated cell sorting (FACS) analysis was
performed to control mast cell differentiation.
Histamine release by murine bone marrow–derived
mast cells
After 4 weeks of cell culture, mast cells were resuspended in warm
Tyrode buffer (1 3 107 cells/mL of buffer) and incubated with 10 mg/mL
purified mouse IgE, k isotype control antibody (BioLegend, Fell, Germany)
for 30 minutes at 378C. Afterward, cells werewashed twicewith warm Tyrode
buffer and centrifuged for 5 minutes at 48C and 1500 rpm. The cell pellet was
then resuspended again in warm Tyrode buffer (5 3 106 cells/mL of buffer)
and incubated with TNP-conjugated BSA (Santa Cruz Biotechnology,
Heidelberg, Germany) for 10minutes at 378C. Thereafter, 1mLof cold Tyrode
buffer was added, and cells were centrifuged for 5 minutes at 48C
and 1500 rpm. Supernatants were collected, and the cell pellet was
resuspended in Tyrode buffer. Then, cells and supernatants were boiled for
10 minutes at 998C and frozen at 2808C until the ELISA for histamine was
performed.
Some of the mast cells were plated in a 96-well plate overnight withmedium
and cytokines and serum (1:1 media and serum) from OVA-sensitized and
challenged NFATc1fl/fl control mice and NFATc1fl/flxCD4Cre mice. The next
day, cellswere resuspended and incubated inwarmTyrode bufferwithOVApep-
tide (500 mg/mL; SINFEKL) for 20 minutes at 378C. Afterward, 1 mL of cold
Tyrode buffer was added, and cells were centrifuged for 5 minutes at 48C and
1500 rpm. Supernatants were collected, and cell pellets were resuspended in
Tyrode buffer. Thereafter, cells and supernatants were boiled for 10 minutes at
998C and then frozen at2808C until ELISA for histamine was performed.
Flow cytometric analysis
Brochoalveolar lavage (BAL) of the right lung was performed with 0.8 mL
of saline 2 times. Total BAL fluid was collected and centrifuged for 5 minutes
at 48C. Cell pellets were resuspended in 1 mL of PBS and used for FACS
analysis. BAL fluid cells and bone marrow–derived mast cells were stained
with FACS antibodies for 30 minutes at 48C, washed in PBS, and then
analyzed with a FACSCalibur (BD PharMingen, Heidelberg, Germany). The
following antibodies were used: anti-mouse FcεRI, CD123, and c-kit
antibodies (eBioscience, Frankfurt, Germany). Afterward, measurements
were analyzed with FlowJo software (TreeStar, Ashland, Ore).
ELISA
Human and mouse IL-9 were detected by using a Ready-SET-Go! ELISA
kit from eBioscience (sensitivity, 1 pg/mL). Murine serum IgE was
detected with the OptEIA sandwich ELISA kit from BD Biosciences
(1562-100 ng/mL), and OVA-specific IgE was detected with the LEGEND
MAX ELISA kit from BioLegend (sensitivity, 20.7 pg/mL). Histamine was
measured with Histamine ELISA Fast Track (sensitivity, 0.2 ng/mL; Labor
Diagnostika Nord GmbH, Nordhorn, Germany).
RNA isolation and quantitative real time-PCR
PBMCswere directly lysed, and total RNAwas extracted by using PeqGold
RNA Pure, according to the manufacturer’s protocol (PeqLab, Erlangen,
Germany). The RNA concentration was determined by using a
spectrophotometer (Nanodrop; Peqlab, Erlangen, Germany). RNA was then
reverse transcribed with the first-strand cDNA synthesis kit (MBI Fermentas,
St Leon-Rot, Germany). The resulting cDNA was amplified by means of
quantitative real-time PCR with SsoFast EvaGreen Supermix (Bio-Rad
Laboratories, Munich, Germany). Quantitative real-time PCR was performed
with a cycle of 2minutes at 988C; 50 cycles of 5 seconds at 958C, 10 seconds at
608C, and 5 seconds at 658C; and 5 seconds at 958C in a CFX96 Touch
Real-Time PCR Detection System (Bio-Rad Laboratories).
The following primers and sequences were used:
d human hypoxanthine phosphoribosyltransferase 1 (HPRT): 59-TGA-
CACTGGCAAAACAATGCA-39 and 59-GGTCCTTTTCACCAGCA
AGCT-39;
d human IFNG: 59-TGA CCAGAG CAT CCA AAAGA-39 and 59- TGA
CCA GAG CAT CCA AAA GA-39;
d human IRF4: 59-AGACTGTGCCAGAGCAGGAT-39 and 59-GGGTC
TGGAAACTCCTCTCC-39;
d human NFATc1: 59- GCATCACAGGGAAGACCGTGTC-39 and 59-GAA
GTTCAATGTCGGAGTTTCTGAG-39;
d murine Hprt: 59-GCCCCAAAATGGTTAAGGTT-39 and 59-TTGC
GCTCATCTTAGGCTTT;
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d murine Irf4: 59-ACGCTGCCCTCTTCAAGGCTT-39 and 59-TGG
CTCCTCTCGACCAATTCC-39; and
d murine Nfatc1/A: 59-ACCTGTGCAAGCCAAATTCC-39 and 59-AGA
GTTACCATTGGCAGGAAG-39.
The mRNA expression was normalized to HPRT, and FC differences were
calculated by using the DD cycle threshold method.
Statistical analysis
Differences were evaluated for significance by using the Student 2-tailed t
test for independent events (PreDicta study, murine model). The coefficient of
correlations was calculated by using statistical analysis in Excel software.
Data are presented as means 6 SEMs. For the Asthma BRIDGE Study, the
R Bioconductor limma package (version 3.20.1) was used to perform
differential expression analysis in gene microarray analyses.
RESULTS AND DISCUSSION
To further explore our human data on NFATc1, we further
analyzed the recently described mice that lack NFAC1 in T cells
(NFATc1fl/flxCD4Cre) in a murine model of asthma. IL-9 is a crit-
ical cytokine in the pathogenesis of allergic asthma, levels of
which were found to be upregulated in asthmatic patients with a
positive skin test result. Thus we next examined IL-9 production
in a murine model of asthma in the absence of NFATc1 in T cells
(Fig E1, A and B). In isolated lung CD41 T cells we found that
IL-9 levels were decreased in allergen-sensitized and challenged
NFATc1fl/flxCD4Cre mice compared with those in NFATc1fl/fl
control mice (Fig E1, B). By contrast, Irf4 was found not to be
regulated by NFATc1 (Fig E1, C). Finally, we found an almost
perfect direct correlation between OVA-specific IgE levels in
the serum and Nfatc1/A in lung CD41 T cells (Fig E1, D) in
this model of allergic asthma. Irf4 also positively correlated
with OVA-specific IgE levels in serum but not as much as
Nfatc1/A (Fig E1, E).
Although our data suggest that NFATc1 does not influence the
expression of IRF4, it is already known that IRF4 cooperates and
interacts with NFAT.E13 It might be that this interaction is reduced
in the conditional NFATc1 knockout mice, and this could explain
the reduced production of IL-9 in the absence of NFATc1.
IRF4 is known to be essential for IL-9 production, and now we
found that NFATc1 also has an effect on IL-9 production either
through a direct effect on the promoter of IL-9 (alone or along
with IRF4) or through its influence on IL-2E14 or IL-4, which are
required for IL-9 production. In fact, TGF-b and IL-4 are required
to induce TH9 differentiation.
E15
IL-9 has been shown to be a growth factor for mast cells.E16,E17
Thus we investigated the number of mast cells in the BAL fluid of
NFATc1fl/fl control and NFATc1fl/flxCD4Cremice (Fig E2,A).We
observed that mast cell numbers are significantly increased after
allergen sensitization and challenge in NFATc1fl/fl control mice
compared with those in NFATc1fl/flxCD4Cre mice (Fig E2, A).
Because the number of mast cells is decreased in the absence of
NFATc1 in T cells and because IgE crosslinking on the surfaces
of mast cells leads to their activation and degranulation, we also
investigated serum levels of IgE.We could observe that sensitized
and challenged NFATc1fl/flxCD4Cre mice had lower total levels
of IgE in their serum than NFATc1fl/fl control mice (Fig E2, B).
OVA-specific IgE levels are also significantly reduced in our
asthma model in Nfatc1fl/flxCD4Cre mice compared with those in
control mice.E2 Moreover, we reported here that OVA-specific
IgE levels directly correlated with NFATc1 in a model of allergic
asthma. In addition, we previously reported that reduced expres-
sion of CD40 ligand on CD4 T cells of Nfatc1fl/flxCD4Cre mice
indicates a reduced interaction between the T and B cells in these
mice, which results in lower IgE production.E2
NFATc1 is known to be expressed in mast cells, where it
influences the production of IL-13 and TNF-a after FcεRI signal
induction, without influencing the differentiation and activation
of these cells.E17 IgE levels in serum were also found to be
downregulated in the absence of NFATc1 in asthmatic mice.
IL-9 is known to be produced bymast cells in an autocrinemanner
after IgE crosslinking. It then promotes the release of numerous
preformed mediators, such as histamine and IL-1b, which further
induce IL-9 production and several cytokines, including IL-5 and
IL-13.E18
We then went on to further analyze the effect of IL-9 on mast
cell differentiation, expansion, and histamine release. To this
aim, we differentiated mast cells from the bone marrow of
NFATc1fl/fl control mice and NFATc1fl/flxCD4Cre mice for
4 weeks (Fig E2, C). Mast cells from NFATc1fl/fl control mice
were then cultured overnight with serum from OVA-sensitized
and challenged NFATc1fl/fl control mice, and mast cells from
NFATc1fl/flxCD4Cre mice were cultured with serum from OVA
sensitized and challenged NFATc1fl/flxCD4Cre mice. The next
day, differentiated mast cells were incubated with OVA peptide
(SINFEKL) and analyzed for histamine release (Fig E2, C). We
observed that mast cells from both mouse strains incubated
with OVA peptide and IL-9 had induced histamine release from
mast cells. Additionally, the mast cells from NFATc1fl/flxCD4Cre
mice cultured with IL-9 showed reduced histamine release
compared with those isolated from NFATc1
fl/fl
control mice
(Fig E2, C). Together, these data demonstrate that mast cell
activation with the specific peptide used to sensitize mice leads
to increased histamine release in sensitized mast cells in the
presence of NFATc1 and IL-9, suggesting that the NFATc1
deficiency in T cells results in defective IgE production, which
affects IgE-orchestrated mast cell activation mediated through
IL-9.
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FIG E1. Decreased IL-9 production in NFATc1fl/flxCD4Cre mice after allergen sensitization and challenge.
A, Experimental design of the OVA-induced asthma model. B, IL-9 protein concentrations were measured
in supernatants of purified lung CD41 T cells from allergen-treated mice and cultured for 24 hours with
a-CD3 and a-CD28 antibodies (n 5 7-11 mice per group). C, Irf4 mRNA expression measured by using
quantitative real-time PCR in isolated lung CD41 T cells (n 5 8-13 mice per group). D, Correlation between
Nfatc1/A mRNA expression in lung CD41 T cells and OVA-specific IgE levels in serum of Nfatc1fl/fl
OVA-treated mice (n 5 6). E, Correlation between Irf4 mRNA expression in lung CD41 T cells and
OVA-specific IgE in serum of Nfatc1fl/fl OVA mice (n 5 6). The Student t test was used to evaluate statistical
significance. *P <_ .05. Data are presented as means 6 SEMs.
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FIG E2. Decreased mast cell numbers and activation in NFATc1fl/flxCD4Cre mice. A, Mast cell numbers
(c-kit1FcεRI1CD1231 cells) were analyzed by using flow cytometry in the lungs of NFATc1fl/fl control mice
and NFATc1fl/flx CD4Cre mice (n 5 4-11 mice per group). B, IgE serum levels were measured with ELISA
(n 5 12-19 mice per group). C, Experimental design for bone marrow–derived mast cell (BMMC) differenti-
ation (upper panel) and histamine release (lower panel). Histamine release was measured by means of
ELISA (lower panel; n 5 4 mice per group). Mast cells differentiated from Nfatc1fl/flxCD4Cre mice received
serum fromOVA-sensitized and challenged Nfatc1fl/flxCD4Cre mice, whereas mast cells fromNfatc1fl/fl mice
received serum from OVA-sensitized and challenged Nfatc1fl/fl mice. Statistical significances in this figure
were evaluated with the Student t test. *P <_ .05, **P <_ .01, and ***P <_ .001. Data are presented as
means 6 SEMs.
J ALLERGY CLIN IMMUNOL
JUNE 2016
1902.e6 LETTERS TO THE EDITOR
FIG E3. Mast cell differentiation. A, Flow cytometric analysis of bone marrow–derived mast cell
differentiation, as described in the Methods section in this article’s Online Repository. FACS analysis for
FcεRI1c-kit1 cells was performed every week to monitor the differentiation status of the cultured cells.
B, Corresponding dot plots from the first and fourth weeks of mast cell differentiation are shown.
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